Streetbeat News

Stock Prices

FLEX

Flex (NASDAQ:FLEX) has set December 29, 2023, as the record date for the spin-off of its interest in Nextracker Inc. to Flex shareholders, with the distribution date on January 2, 2024. Shareholders will receive one share of Yuma Inc. for each Flex share held, which will then be converted into approximately 0.17 shares of Nextracker Class A common stock after Yuma merges with a Nextracker subsidiary. The Singapore High Court has approved the necessary steps under Singapore law, and no further action is required from Flex shareholders. The distribution and merger are based on the Merger Agreement from February 7, 2023, and may be delayed if conditions are not met. Shareholders are advised to consult tax advisors regarding the consequences of the transaction.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 9:06 pm

ALGN

Align Technology, Inc. (NASDAQ:ALGN) shares have risen following two significant regulatory updates. Health Canada updated the medical device license for Align's Invisalign Palatal Expander System last week, leading to a 15% increase in share price. On Monday, the U.S. FDA cleared the product for U.S. commercial availability, further boosting the stock. Shares closed up 2.62% at $261.69.

Portfolio Pulse from Ryan Gustafson

December 18, 2023 | 9:06 pm

NXU

Nxu has received approval from Nasdaq to continue its listing, with the condition that it demonstrates compliance with the listing rules by April 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 9:05 pm

ALDX

Aldeyra Therapeutics, Inc. will host a conference call and webcast on December 19, 2023, to announce Phase 2 clinical trial results for ADX-629, a treatment for atopic dermatitis. The event will be accessible live and archived for 90 days on Aldeyra's website.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 9:03 pm

BLUE

bluebird bio, Inc. has announced a proposed public offering of $150 million of its common stock. The offering is expected to increase the company's cash reserves, potentially diluting current shareholders' equity.

Portfolio Pulse from Bill Haddad

December 18, 2023 | 9:01 pm

WELL

Welltower (NYSE:WELL) has received updated ratings and price targets from 9 financial analysts in the last quarter. The average 12-month price target is $93.22, with a high of $101.00 and a low of $83.00. The ratings are mostly bullish or neutral, with 1 bullish, 4 somewhat bullish, and 4 indifferent. Notably, the average price target has increased by 3.91% over the past month. Welltower's financial health indicators show a strong market presence, positive revenue trend, but below-average net margin and ROE, with an exceptional ROA and a balanced debt approach.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:01 pm

SYF

Synchrony Financial (NYSE:SYF) has been rated by 10 analysts in the last quarter with 2 bullish, 4 somewhat bullish, 2 indifferent, and 2 somewhat bearish ratings. The average 12-month price target is $35.2, down 4.56% from the previous $36.88. Analysts from firms like Goldman Sachs, JMP Securities, Piper Sandler, Morgan Stanley, JP Morgan, HSBC, and Citigroup have adjusted their price targets and ratings, reflecting their views on the company's market position and financial performance. Synchrony Financial has shown strong financial indicators such as a 19.21% revenue growth rate, a net margin of 17.78%, and a ROE of 4.81%.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

ISRG

Intuitive Surgical (NASDAQ:ISRG) has significantly outperformed the market, with an average annual return of 29.56% over the past 20 years. An initial investment of $1000 in ISRG stock 20 years ago would be worth $179,460.33 today. The company currently has a market capitalization of $115.91 billion.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

LMT

Over the past 10 years, Lockheed Martin (NYSE:LMT) has produced an average annual return of 11.81%, outperforming the market by 1.86% on an annualized basis. A $100 investment in LMT a decade ago would be worth $307.63 today. Lockheed Martin's market capitalization currently stands at $110.71 billion.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

REGN

Over the past 3 months, 14 Wall Street analysts have published their opinions on Regeneron Pharmaceuticals (NASDAQ:REGN), with an average 12-month price target of $920.0, a high of $1045.00, and a low of $800.00. The current average price target has increased by 4.74% from the previous average of $878.38. Analysts' ratings range from 'Buy' to 'Hold', with various actions taken including maintaining, raising, and lowering price targets. Regeneron is involved in developing treatments for various diseases and has several marketed products. Financially, the company shows strong performance with a high net margin and ROE, low debt-to-equity ratio, but a revenue growth rate lower than the Health Care sector average.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm